 
										 	
										 	
										 		 
										 	
										 	
										 		 
										 	
										 	
										 		 
										 	
										 	
										 		 
											 	
											 	
											 		Abstract: The aim of this study was to investigate adverse reactions to Dolutegravir, a drug recently made available by the Unified Health System (SUS) for treating HIV infections. The frequency, severity and sex distribution of adverse reactions to Dolutegravir were i
en

 
					 
					 
					 
					 
								 desde Redalyc
   desde Redalyc




 {{t.formats.viewer}}
{{t.formats.viewer}}
				 PDF
PDF
				 HTML
HTML		
				 {{t.formats.mobile}}
 {{t.formats.mobile}}
				 ePUB
 ePUB
				 XML JATS
 XML JATS
				 {{t.titulosSecciones.citas}}
                    {{t.titulosSecciones.citas}} {{t.titulosSecciones.autorias}}
                	{{t.titulosSecciones.autorias}}
                 {{t.titulosSecciones.descargas}}
	                {{t.titulosSecciones.descargas}}
               	 {{t.titulosSecciones.revision}}
                	{{t.titulosSecciones.revision}}
                 
  
					
 
												